Lung Cancer Mortality Among Smokers and Never-Smokers in the United States
No abstract available
Publication date: Available online 29 May 2020Source: Respiratory InvestigationAuthor(s): Yoshiaki Kinoshita, Hiroshi Ishii, Yoshinobu Eishi, Keisuke Uchida, Masayo Yoshimura, Akinori Iwasaki, Masaki Fujita, Kazuki Nabeshima, Kentaro Watanabe
We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for>12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria. PMID: 32461525 [PubMed - as supplied by publisher]
Abstract It is already known that adult height is a factor associated with an increased risk of colon cancer and postmenopausal breast cancer, pancreatic cancer, premenopausal breast cancer, and ovarian cancer. However, the association between adult height and lung cancer incidence remains unclear. The purpose of the present study was to examine the association between adult height and the risk of lung cancer incidence in the Japanese population. We analyzed data for 43,743 men and women who were 40-64 years old at the baseline in 1990. We divided the participants into quintiles based on height at the baseline. Co...
Authors: Bilkhu R, Billè A Abstract The coronavirus 2019 (COVID-19) pandemic has caused significant mortality around the world and the focus has been on reducing the number of infections. In order not to compromise treatment of oncology patients, reducing the number of patients with COVID-19 undergoing treatment is mandatory. We reviewed the experience of the National Institute of Cancer in Milan and compared it with our experience. PMID: 32462984 [PubMed - as supplied by publisher]
ConclusionT-cirDNA could be a novel biomarker representing adaptive immune resistance in NSCLC patients. Further exploration as a predictive biomarker for EGFR inhibitors in setting ofEGFR mutation might be warranted.
ConclusionRegardless of the NSCLC patients who were less or more than 65 years, immune checkpoint inhibitors could achieve better OS than chemotherapy. But there was no significant difference when NSCLC patients who were more than 75 years old. Older patient should be offered immune therapies if it is possible and the mechanism in old age treatment should be further s tudied.
Publication date: Available online 28 May 2020Source: Cancer CellAuthor(s): Arnaud Augert, Haritha Mathsyaraja, Ali H. Ibrahim, Brian Freie, Michael J. Geuenich, Pei-Feng Cheng, Sydney P. Alibeckoff, Nan Wu, Joseph B. Hiatt, Ryan Basom, Adi Gazdar, Lucas B. Sullivan, Robert N. Eisenman, David MacPherson
CONCLUSION: While pembrolizumab is superior to standard chemotherapy in improving overall survival and progression-free survival, results suggest that it is unlikely to be cost-effective at its current price in Singapore. Factors including clinical effectiveness, safety and budget impact should also be considered when making national funding decisions. PMID: 32462958 [PubMed - as supplied by publisher]
J. Huentelman Canine idiopathic pulmonary fibrosis (CIPF) is a chronic fibrotic lung disease that is observed at a higher frequency in the West Highland White Terrier dog breed (WHWT) and may have molecular pathological overlap with human lung fibrotic disease. We conducted a genome-wide association study (GWAS) in the WHWT using whole genome sequencing (WGS) to discover genetic variants associated with CIPF. Saliva-derived DNA samples were sequenced using the Riptide DNA library prep kit. After quality controls, 28 affected, 44 unaffected, and 1,843,695 informative single nucleotide polymorphisms (SNPs) were included ...
LUNG cancer is one of the most common and serious types of cancer, with around 47,000 people are diagnosed with the condition every year in the UK. There are usually no signs or symptoms in the early stages, but as the cancer progresses, you may experience an uncomfortable sensation in your shoulder or chest.